Date: 2015-12-15
Type of information: Series B financing round
Company: GamaMabs Pharma (France)
Investors: Edmond de Rothschild Investment Partners (EdRIP) (France) InnoBio (France) Irdinov (France) Alto Invest (France) iXO Private Equity) (France)
Amount: €15 million
Funding type: series B financing round
Planned used: The fundraising will primarily fund the phase I and phase II clinical trials of GM102 (3C23K), a monoclonal antibody targeting gynecological cancers. GM102 is a first-in-class antibody and the company’s most advanced product. It targets AMHRII, a protein expressed on tumor cell’s membrane surface in various gynecological cancers. It also activates immune cells present in the tumor microenvironment. The first-in-man clinical trials of GM102 will start in the first half of 2016.
Others: * On December 15, 2015, GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies for the treatment of cancer, announced the completion of a €15 million ($15.9 million) series B financing round. The round was led by a new investor, BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners (EdRIP). All existing GamaMabs investors (InnoBio, Irdinov, Alto Invest, iXO Private Equity) also subscribed to the round. The company raised €3.6m ($3.8m) in 2013 in a series A funding round led by InnoBio (Bpifrance). Following the fundraising, Gilles Nobécourt, partner at EdRIP, and Prof. Thierry Hercend will join GamaMabs Pharma’s board of directors.
Therapeutic area: Cancer - Oncology
